Energizer Lifts FY21 Adj. EPS View

Energizer Holdings Inc. (ENR) said that it has updated its full year fiscal 2021 outlook for revenue growth and Adjusted EBITDA to the high end of its previously disclosed range and its adjusted earnings per share range to $3.10 - $3.40. Analysts polled by Thomson Reuters expect the company to report earnings of $3.01 per share for fiscal year 2021. Analysts' estimates typically exclude special items.

The company said it November that it expected 2% to 4% organic revenue growth, adjusted EBITDA in the range of $600 to $630 million and adjusted earnings per share in the range of $2.95 to $3.25 for fiscal 2021.

The company said Monday that it expects no change to the adjusted free cash flow range based on working capital investments planned in the back half of fiscal 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT